A new targeted therapy is significantly improving lung cancer patient outcomes. The drug is called Osimertinib, or brand name ...

FX-909, a first-in-class investigational oral small molecule inhibitor of peroxisome proliferator-activated receptor gamma ...

A review of recent literature shows bioengineering is reshaping oncology, from synthetic biology to nanomedicine, but what's ...

The phase 3 PSMAddition trial demonstrated that the radioligand therapy Lutetium-177 PSMA-617 (Pluvicto) provides a ...

Results from a trial led by researchers from The University of Texas MD Anderson Cancer Center showed that a targeted therapy ...

The oral targeted therapy sevabertinib led to tumor reduction and manageable side effects in patients with HER2-mutant non-small cell lung cancer (NSCLC), according to data from a trial led by ...

The 2025 ESMO annual meeting featured a metastatic castration-resistant prostate cancer (mCRPC) session and a presentation by ...

Six out of ten patients experienced complete responses in treated tumors with an additional two patients demonstrating partial responses – confirmed in a representative tumor biopsy – all within ...

Recent studies reveal that triplet therapies significantly enhance progression-free survival in patients with ...

Actress Dipika Kakar revealed her liver cancer diagnosis during her Diwali celebration vlog, sharing that she is experiencing ...

A team of researchers at The University of Texas at Austin and the University of Porto have created a new way to target cancer—tin-based nanomaterials combined with near-infrared light. Their work has ...